nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—ADRA1B—vas deferens—prostate cancer	0.0813	0.656	CbGeAlD
Dextroamphetamine—CYP2D6—Bicalutamide—prostate cancer	0.0511	0.505	CbGbCtD
Dextroamphetamine—CYP2D6—Abiraterone—prostate cancer	0.0423	0.418	CbGbCtD
Dextroamphetamine—CYP2D6—Doxorubicin—prostate cancer	0.00783	0.0773	CbGbCtD
Dextroamphetamine—SLC18A2—prostate gland—prostate cancer	0.00719	0.058	CbGeAlD
Dextroamphetamine—CYP2D6—urine—prostate cancer	0.00669	0.054	CbGeAlD
Dextroamphetamine—ADRA1B—renal system—prostate cancer	0.00495	0.0399	CbGeAlD
Dextroamphetamine—ADRA1A—prostate gland—prostate cancer	0.00408	0.0329	CbGeAlD
Dextroamphetamine—SLC18A2—testis—prostate cancer	0.00317	0.0256	CbGeAlD
Dextroamphetamine—ADRA1A—epithelium—prostate cancer	0.003	0.0242	CbGeAlD
Dextroamphetamine—ADRA1A—renal system—prostate cancer	0.00278	0.0224	CbGeAlD
Dextroamphetamine—SLC6A3—testis—prostate cancer	0.00239	0.0193	CbGeAlD
Dextroamphetamine—SLC18A2—lymph node—prostate cancer	0.00229	0.0185	CbGeAlD
Dextroamphetamine—SLC6A2—testis—prostate cancer	0.00193	0.0156	CbGeAlD
Dextroamphetamine—CYP2D6—renal system—prostate cancer	0.00164	0.0132	CbGeAlD
Dextroamphetamine—Phenelzine—CYP3A43—prostate cancer	0.00151	0.112	CrCbGaD
Dextroamphetamine—SLC6A2—lymph node—prostate cancer	0.0014	0.0113	CbGeAlD
Dextroamphetamine—Pseudoephedrine—IL2—prostate cancer	0.00117	0.0867	CrCbGaD
Dextroamphetamine—CYP2D6—testis—prostate cancer	0.00106	0.00854	CbGeAlD
Dextroamphetamine—L-Phenylalanine—TH—prostate cancer	0.000971	0.0721	CrCbGaD
Dextroamphetamine—Ephedrine—ACHE—prostate cancer	0.000911	0.0677	CrCbGaD
Dextroamphetamine—Phenformin—SLC22A1—prostate cancer	0.000843	0.0627	CrCbGaD
Dextroamphetamine—Amphetamine—SLC22A3—prostate cancer	0.000619	0.046	CrCbGaD
Dextroamphetamine—Methamphetamine—SLC22A3—prostate cancer	0.000573	0.0426	CrCbGaD
Dextroamphetamine—Tranylcypromine—CYP2A6—prostate cancer	0.000538	0.0399	CrCbGaD
Dextroamphetamine—Ephedrine—ADRB2—prostate cancer	0.00046	0.0342	CrCbGaD
Dextroamphetamine—Selegiline—CYP2A6—prostate cancer	0.000417	0.031	CrCbGaD
Dextroamphetamine—Phenylpropanolamine—ADRB2—prostate cancer	0.000413	0.0307	CrCbGaD
Dextroamphetamine—Nateglinide—CYP3A5—prostate cancer	0.000385	0.0286	CrCbGaD
Dextroamphetamine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000383	0.000743	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Prednisone—prostate cancer	0.000382	0.000742	CcSEcCtD
Dextroamphetamine—Tranylcypromine—CYP2E1—prostate cancer	0.000382	0.0284	CrCbGaD
Dextroamphetamine—Phenelzine—CYP3A5—prostate cancer	0.000379	0.0282	CrCbGaD
Dextroamphetamine—Tranylcypromine—CYP2C19—prostate cancer	0.000378	0.0281	CrCbGaD
Dextroamphetamine—Mood swings—Epirubicin—prostate cancer	0.000375	0.000727	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000374	0.000725	CcSEcCtD
Dextroamphetamine—Dizziness—Goserelin—prostate cancer	0.000374	0.000725	CcSEcCtD
Dextroamphetamine—Dyspnoea—Mitoxantrone—prostate cancer	0.000372	0.000722	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Capecitabine—prostate cancer	0.000372	0.000721	CcSEcCtD
Dextroamphetamine—Somnolence—Mitoxantrone—prostate cancer	0.000371	0.00072	CcSEcCtD
Dextroamphetamine—Dizziness—Conjugated Estrogens—prostate cancer	0.00037	0.000718	CcSEcCtD
Dextroamphetamine—Convulsion—Etoposide—prostate cancer	0.000369	0.000715	CcSEcCtD
Dextroamphetamine—Dyspepsia—Mitoxantrone—prostate cancer	0.000367	0.000713	CcSEcCtD
Dextroamphetamine—Hypertension—Etoposide—prostate cancer	0.000367	0.000712	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Estradiol—prostate cancer	0.000366	0.00071	CcSEcCtD
Dextroamphetamine—Decreased appetite—Mitoxantrone—prostate cancer	0.000363	0.000704	CcSEcCtD
Dextroamphetamine—Chest pain—Etoposide—prostate cancer	0.000362	0.000702	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Epirubicin—prostate cancer	0.000362	0.000701	CcSEcCtD
Dextroamphetamine—Affect lability—Doxorubicin—prostate cancer	0.000361	0.000699	CcSEcCtD
Dextroamphetamine—Fatigue—Mitoxantrone—prostate cancer	0.00036	0.000698	CcSEcCtD
Dextroamphetamine—Vomiting—Goserelin—prostate cancer	0.000359	0.000697	CcSEcCtD
Dextroamphetamine—Constipation—Mitoxantrone—prostate cancer	0.000357	0.000692	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000357	0.000692	CcSEcCtD
Dextroamphetamine—Rash—Goserelin—prostate cancer	0.000356	0.000691	CcSEcCtD
Dextroamphetamine—Dermatitis—Goserelin—prostate cancer	0.000356	0.00069	CcSEcCtD
Dextroamphetamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000356	0.00069	CcSEcCtD
Dextroamphetamine—Urticaria—Estradiol—prostate cancer	0.000356	0.00069	CcSEcCtD
Dextroamphetamine—Body temperature increased—Estradiol—prostate cancer	0.000354	0.000687	CcSEcCtD
Dextroamphetamine—Abdominal pain—Estradiol—prostate cancer	0.000354	0.000687	CcSEcCtD
Dextroamphetamine—Headache—Goserelin—prostate cancer	0.000354	0.000687	CcSEcCtD
Dextroamphetamine—Rash—Conjugated Estrogens—prostate cancer	0.000353	0.000684	CcSEcCtD
Dextroamphetamine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000353	0.000684	CcSEcCtD
Dextroamphetamine—Headache—Conjugated Estrogens—prostate cancer	0.000351	0.00068	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—ADRB2—prostate cancer	0.000349	0.0259	CrCbGaD
Dextroamphetamine—Anaphylactic shock—Etoposide—prostate cancer	0.000347	0.000673	CcSEcCtD
Dextroamphetamine—Mood swings—Doxorubicin—prostate cancer	0.000347	0.000673	CcSEcCtD
Dextroamphetamine—Amphetamine—CYP2A6—prostate cancer	0.000346	0.0257	CrCbGaD
Dextroamphetamine—Infection—Etoposide—prostate cancer	0.000345	0.000669	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000341	0.000662	CcSEcCtD
Dextroamphetamine—Tachycardia—Etoposide—prostate cancer	0.000339	0.000657	CcSEcCtD
Dextroamphetamine—Nausea—Goserelin—prostate cancer	0.000336	0.000651	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Etoposide—prostate cancer	0.000336	0.000651	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Doxorubicin—prostate cancer	0.000335	0.000649	CcSEcCtD
Dextroamphetamine—Nausea—Conjugated Estrogens—prostate cancer	0.000333	0.000645	CcSEcCtD
Dextroamphetamine—Urticaria—Mitoxantrone—prostate cancer	0.000332	0.000643	CcSEcCtD
Dextroamphetamine—Anorexia—Etoposide—prostate cancer	0.000331	0.000642	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Estradiol—prostate cancer	0.00033	0.00064	CcSEcCtD
Dextroamphetamine—Body temperature increased—Mitoxantrone—prostate cancer	0.00033	0.00064	CcSEcCtD
Dextroamphetamine—Abdominal pain—Mitoxantrone—prostate cancer	0.00033	0.00064	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.00033	0.00064	CcSEcCtD
Dextroamphetamine—Asthenia—Estradiol—prostate cancer	0.000321	0.000623	CcSEcCtD
Dextroamphetamine—Tremor—Capecitabine—prostate cancer	0.000321	0.000622	CcSEcCtD
Dextroamphetamine—Palpitations—Docetaxel—prostate cancer	0.000312	0.000606	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Epirubicin—prostate cancer	0.000312	0.000606	CcSEcCtD
Dextroamphetamine—Weight decreased—Epirubicin—prostate cancer	0.00031	0.0006	CcSEcCtD
Dextroamphetamine—Dyspnoea—Etoposide—prostate cancer	0.00031	0.0006	CcSEcCtD
Dextroamphetamine—Somnolence—Etoposide—prostate cancer	0.000309	0.000599	CcSEcCtD
Dextroamphetamine—Benzyl alcohol—CYP2E1—prostate cancer	0.000309	0.0229	CrCbGaD
Dextroamphetamine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000308	0.000596	CcSEcCtD
Dextroamphetamine—Diarrhoea—Estradiol—prostate cancer	0.000307	0.000594	CcSEcCtD
Dextroamphetamine—Convulsion—Docetaxel—prostate cancer	0.000306	0.000594	CcSEcCtD
Dextroamphetamine—Hypertension—Docetaxel—prostate cancer	0.000305	0.000592	CcSEcCtD
Dextroamphetamine—Benzyl alcohol—CYP1A1—prostate cancer	0.000304	0.0226	CrCbGaD
Dextroamphetamine—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000303	0.000587	CcSEcCtD
Dextroamphetamine—Palpitations—Capecitabine—prostate cancer	0.000303	0.000587	CcSEcCtD
Dextroamphetamine—Decreased appetite—Etoposide—prostate cancer	0.000302	0.000585	CcSEcCtD
Dextroamphetamine—Chest pain—Docetaxel—prostate cancer	0.000301	0.000584	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Etoposide—prostate cancer	0.0003	0.000581	CcSEcCtD
Dextroamphetamine—Asthenia—Mitoxantrone—prostate cancer	0.0003	0.000581	CcSEcCtD
Dextroamphetamine—Fatigue—Etoposide—prostate cancer	0.000299	0.000581	CcSEcCtD
Dextroamphetamine—Constipation—Etoposide—prostate cancer	0.000297	0.000576	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Epirubicin—prostate cancer	0.000297	0.000575	CcSEcCtD
Dextroamphetamine—Dizziness—Estradiol—prostate cancer	0.000296	0.000574	CcSEcCtD
Dextroamphetamine—Selegiline—CYP2E1—prostate cancer	0.000296	0.022	CrCbGaD
Dextroamphetamine—Hypertension—Capecitabine—prostate cancer	0.000296	0.000573	CcSEcCtD
Dextroamphetamine—Dry mouth—Docetaxel—prostate cancer	0.000294	0.000571	CcSEcCtD
Dextroamphetamine—Selegiline—CYP2C19—prostate cancer	0.000293	0.0218	CrCbGaD
Dextroamphetamine—Sweating—Epirubicin—prostate cancer	0.000293	0.000567	CcSEcCtD
Dextroamphetamine—Chest pain—Capecitabine—prostate cancer	0.000291	0.000565	CcSEcCtD
Dextroamphetamine—Anxiety—Capecitabine—prostate cancer	0.00029	0.000563	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Doxorubicin—prostate cancer	0.000289	0.000561	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Docetaxel—prostate cancer	0.000289	0.00056	CcSEcCtD
Dextroamphetamine—Infection—Docetaxel—prostate cancer	0.000287	0.000556	CcSEcCtD
Dextroamphetamine—Weight decreased—Doxorubicin—prostate cancer	0.000287	0.000556	CcSEcCtD
Dextroamphetamine—Diarrhoea—Mitoxantrone—prostate cancer	0.000286	0.000554	CcSEcCtD
Dextroamphetamine—Dry mouth—Capecitabine—prostate cancer	0.000285	0.000553	CcSEcCtD
Dextroamphetamine—Vomiting—Estradiol—prostate cancer	0.000285	0.000552	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Etoposide—prostate cancer	0.000284	0.000551	CcSEcCtD
Dextroamphetamine—Rash—Estradiol—prostate cancer	0.000282	0.000548	CcSEcCtD
Dextroamphetamine—Dermatitis—Estradiol—prostate cancer	0.000282	0.000547	CcSEcCtD
Dextroamphetamine—Tachycardia—Docetaxel—prostate cancer	0.000282	0.000546	CcSEcCtD
Dextroamphetamine—Headache—Estradiol—prostate cancer	0.000281	0.000544	CcSEcCtD
Dextroamphetamine—Agitation—Prednisone—prostate cancer	0.00028	0.000543	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.00028	0.000543	CcSEcCtD
Dextroamphetamine—Angioedema—Prednisone—prostate cancer	0.000279	0.00054	CcSEcCtD
Dextroamphetamine—Infection—Capecitabine—prostate cancer	0.000278	0.000538	CcSEcCtD
Dextroamphetamine—Urticaria—Etoposide—prostate cancer	0.000276	0.000535	CcSEcCtD
Dextroamphetamine—Anorexia—Docetaxel—prostate cancer	0.000275	0.000533	CcSEcCtD
Dextroamphetamine—Abdominal pain—Etoposide—prostate cancer	0.000274	0.000532	CcSEcCtD
Dextroamphetamine—Body temperature increased—Etoposide—prostate cancer	0.000274	0.000532	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Doxorubicin—prostate cancer	0.000274	0.000532	CcSEcCtD
Dextroamphetamine—Tachycardia—Capecitabine—prostate cancer	0.000273	0.000529	CcSEcCtD
Dextroamphetamine—Sweating—Doxorubicin—prostate cancer	0.000271	0.000525	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Capecitabine—prostate cancer	0.00027	0.000524	CcSEcCtD
Dextroamphetamine—Anorexia—Capecitabine—prostate cancer	0.000266	0.000516	CcSEcCtD
Dextroamphetamine—Nausea—Estradiol—prostate cancer	0.000266	0.000516	CcSEcCtD
Dextroamphetamine—Vomiting—Mitoxantrone—prostate cancer	0.000265	0.000515	CcSEcCtD
Dextroamphetamine—Convulsion—Prednisone—prostate cancer	0.000264	0.000512	CcSEcCtD
Dextroamphetamine—Hypertension—Prednisone—prostate cancer	0.000263	0.000511	CcSEcCtD
Dextroamphetamine—Rash—Mitoxantrone—prostate cancer	0.000263	0.00051	CcSEcCtD
Dextroamphetamine—Dermatitis—Mitoxantrone—prostate cancer	0.000263	0.00051	CcSEcCtD
Dextroamphetamine—Headache—Mitoxantrone—prostate cancer	0.000262	0.000507	CcSEcCtD
Dextroamphetamine—Insomnia—Docetaxel—prostate cancer	0.000261	0.000506	CcSEcCtD
Dextroamphetamine—Phenelzine—CYP2E1—prostate cancer	0.000261	0.0194	CrCbGaD
Dextroamphetamine—Erythema multiforme—Epirubicin—prostate cancer	0.000259	0.000502	CcSEcCtD
Dextroamphetamine—Anxiety—Prednisone—prostate cancer	0.000259	0.000502	CcSEcCtD
Dextroamphetamine—Phenelzine—CYP2C19—prostate cancer	0.000258	0.0192	CrCbGaD
Dextroamphetamine—Dyspnoea—Docetaxel—prostate cancer	0.000257	0.000499	CcSEcCtD
Dextroamphetamine—Somnolence—Docetaxel—prostate cancer	0.000257	0.000497	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Etoposide—prostate cancer	0.000256	0.000496	CcSEcCtD
Dextroamphetamine—Dyspepsia—Docetaxel—prostate cancer	0.000254	0.000493	CcSEcCtD
Dextroamphetamine—Insomnia—Capecitabine—prostate cancer	0.000253	0.00049	CcSEcCtD
Dextroamphetamine—Decreased appetite—Docetaxel—prostate cancer	0.000251	0.000486	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000249	0.000483	CcSEcCtD
Dextroamphetamine—Asthenia—Etoposide—prostate cancer	0.000249	0.000483	CcSEcCtD
Dextroamphetamine—Dyspnoea—Capecitabine—prostate cancer	0.000249	0.000483	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Prednisone—prostate cancer	0.000249	0.000483	CcSEcCtD
Dextroamphetamine—Fatigue—Docetaxel—prostate cancer	0.000249	0.000482	CcSEcCtD
Dextroamphetamine—Nausea—Mitoxantrone—prostate cancer	0.000248	0.000481	CcSEcCtD
Dextroamphetamine—Infection—Prednisone—prostate cancer	0.000247	0.000479	CcSEcCtD
Dextroamphetamine—Constipation—Docetaxel—prostate cancer	0.000247	0.000479	CcSEcCtD
Dextroamphetamine—Dyspepsia—Capecitabine—prostate cancer	0.000246	0.000477	CcSEcCtD
Dextroamphetamine—Tachycardia—Prednisone—prostate cancer	0.000243	0.000471	CcSEcCtD
Dextroamphetamine—Decreased appetite—Capecitabine—prostate cancer	0.000243	0.000471	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000241	0.000468	CcSEcCtD
Dextroamphetamine—Fatigue—Capecitabine—prostate cancer	0.000241	0.000467	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Prednisone—prostate cancer	0.000241	0.000467	CcSEcCtD
Dextroamphetamine—Tranylcypromine—CYP3A4—prostate cancer	0.00024	0.0179	CrCbGaD
Dextroamphetamine—Erythema multiforme—Doxorubicin—prostate cancer	0.00024	0.000465	CcSEcCtD
Dextroamphetamine—Constipation—Capecitabine—prostate cancer	0.000239	0.000463	CcSEcCtD
Dextroamphetamine—Diarrhoea—Etoposide—prostate cancer	0.000238	0.000461	CcSEcCtD
Dextroamphetamine—Anorexia—Prednisone—prostate cancer	0.000237	0.00046	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Docetaxel—prostate cancer	0.000236	0.000458	CcSEcCtD
Dextroamphetamine—Tension—Epirubicin—prostate cancer	0.000234	0.000454	CcSEcCtD
Dextroamphetamine—Nervousness—Epirubicin—prostate cancer	0.000232	0.000449	CcSEcCtD
Dextroamphetamine—Dizziness—Etoposide—prostate cancer	0.00023	0.000445	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Capecitabine—prostate cancer	0.000228	0.000443	CcSEcCtD
Dextroamphetamine—Abdominal pain—Docetaxel—prostate cancer	0.000228	0.000442	CcSEcCtD
Dextroamphetamine—Body temperature increased—Docetaxel—prostate cancer	0.000228	0.000442	CcSEcCtD
Dextroamphetamine—Insomnia—Prednisone—prostate cancer	0.000225	0.000436	CcSEcCtD
Dextroamphetamine—Urticaria—Capecitabine—prostate cancer	0.000222	0.00043	CcSEcCtD
Dextroamphetamine—Abdominal pain—Capecitabine—prostate cancer	0.000221	0.000428	CcSEcCtD
Dextroamphetamine—Body temperature increased—Capecitabine—prostate cancer	0.000221	0.000428	CcSEcCtD
Dextroamphetamine—Vomiting—Etoposide—prostate cancer	0.000221	0.000428	CcSEcCtD
Dextroamphetamine—Agitation—Epirubicin—prostate cancer	0.000219	0.000425	CcSEcCtD
Dextroamphetamine—Dyspepsia—Prednisone—prostate cancer	0.000219	0.000425	CcSEcCtD
Dextroamphetamine—Rash—Etoposide—prostate cancer	0.000219	0.000425	CcSEcCtD
Dextroamphetamine—Dermatitis—Etoposide—prostate cancer	0.000219	0.000424	CcSEcCtD
Dextroamphetamine—Headache—Etoposide—prostate cancer	0.000218	0.000422	CcSEcCtD
Dextroamphetamine—Tension—Doxorubicin—prostate cancer	0.000217	0.00042	CcSEcCtD
Dextroamphetamine—Decreased appetite—Prednisone—prostate cancer	0.000216	0.00042	CcSEcCtD
Dextroamphetamine—Fatigue—Prednisone—prostate cancer	0.000215	0.000416	CcSEcCtD
Dextroamphetamine—Nervousness—Doxorubicin—prostate cancer	0.000214	0.000416	CcSEcCtD
Dextroamphetamine—Constipation—Prednisone—prostate cancer	0.000213	0.000413	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Docetaxel—prostate cancer	0.000213	0.000412	CcSEcCtD
Dextroamphetamine—Palpitations—Epirubicin—prostate cancer	0.000211	0.000409	CcSEcCtD
Dextroamphetamine—Asthenia—Docetaxel—prostate cancer	0.000207	0.000401	CcSEcCtD
Dextroamphetamine—Convulsion—Epirubicin—prostate cancer	0.000207	0.000401	CcSEcCtD
Dextroamphetamine—Nausea—Etoposide—prostate cancer	0.000206	0.0004	CcSEcCtD
Dextroamphetamine—Hypertension—Epirubicin—prostate cancer	0.000206	0.000399	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Capecitabine—prostate cancer	0.000206	0.000399	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Prednisone—prostate cancer	0.000204	0.000395	CcSEcCtD
Dextroamphetamine—Chest pain—Epirubicin—prostate cancer	0.000203	0.000394	CcSEcCtD
Dextroamphetamine—Agitation—Doxorubicin—prostate cancer	0.000203	0.000393	CcSEcCtD
Dextroamphetamine—Anxiety—Epirubicin—prostate cancer	0.000202	0.000392	CcSEcCtD
Dextroamphetamine—Asthenia—Capecitabine—prostate cancer	0.0002	0.000389	CcSEcCtD
Dextroamphetamine—Dry mouth—Epirubicin—prostate cancer	0.000199	0.000385	CcSEcCtD
Dextroamphetamine—Urticaria—Prednisone—prostate cancer	0.000198	0.000383	CcSEcCtD
Dextroamphetamine—Diarrhoea—Docetaxel—prostate cancer	0.000197	0.000383	CcSEcCtD
Dextroamphetamine—Abdominal pain—Prednisone—prostate cancer	0.000197	0.000381	CcSEcCtD
Dextroamphetamine—Body temperature increased—Prednisone—prostate cancer	0.000197	0.000381	CcSEcCtD
Dextroamphetamine—Palpitations—Doxorubicin—prostate cancer	0.000195	0.000378	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Epirubicin—prostate cancer	0.000195	0.000377	CcSEcCtD
Dextroamphetamine—Benzyl alcohol—CYP3A4—prostate cancer	0.000194	0.0144	CrCbGaD
Dextroamphetamine—Infection—Epirubicin—prostate cancer	0.000193	0.000375	CcSEcCtD
Dextroamphetamine—Convulsion—Doxorubicin—prostate cancer	0.000191	0.000371	CcSEcCtD
Dextroamphetamine—Diarrhoea—Capecitabine—prostate cancer	0.000191	0.000371	CcSEcCtD
Dextroamphetamine—Dizziness—Docetaxel—prostate cancer	0.000191	0.00037	CcSEcCtD
Dextroamphetamine—Hypertension—Doxorubicin—prostate cancer	0.000191	0.000369	CcSEcCtD
Dextroamphetamine—Tachycardia—Epirubicin—prostate cancer	0.00019	0.000368	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Epirubicin—prostate cancer	0.000188	0.000365	CcSEcCtD
Dextroamphetamine—Chest pain—Doxorubicin—prostate cancer	0.000188	0.000364	CcSEcCtD
Dextroamphetamine—Anxiety—Doxorubicin—prostate cancer	0.000187	0.000363	CcSEcCtD
Dextroamphetamine—Selegiline—CYP3A4—prostate cancer	0.000186	0.0139	CrCbGaD
Dextroamphetamine—Anorexia—Epirubicin—prostate cancer	0.000186	0.00036	CcSEcCtD
Dextroamphetamine—Dizziness—Capecitabine—prostate cancer	0.000185	0.000358	CcSEcCtD
Dextroamphetamine—Dry mouth—Doxorubicin—prostate cancer	0.000184	0.000356	CcSEcCtD
Dextroamphetamine—Vomiting—Docetaxel—prostate cancer	0.000183	0.000356	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Prednisone—prostate cancer	0.000183	0.000356	CcSEcCtD
Dextroamphetamine—Rash—Docetaxel—prostate cancer	0.000182	0.000353	CcSEcCtD
Dextroamphetamine—Dermatitis—Docetaxel—prostate cancer	0.000182	0.000352	CcSEcCtD
Dextroamphetamine—Headache—Docetaxel—prostate cancer	0.000181	0.000351	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Doxorubicin—prostate cancer	0.00018	0.000349	CcSEcCtD
Dextroamphetamine—Infection—Doxorubicin—prostate cancer	0.000179	0.000347	CcSEcCtD
Dextroamphetamine—Asthenia—Prednisone—prostate cancer	0.000179	0.000346	CcSEcCtD
Dextroamphetamine—Vomiting—Capecitabine—prostate cancer	0.000178	0.000344	CcSEcCtD
Dextroamphetamine—Rash—Capecitabine—prostate cancer	0.000176	0.000342	CcSEcCtD
Dextroamphetamine—Insomnia—Epirubicin—prostate cancer	0.000176	0.000341	CcSEcCtD
Dextroamphetamine—Dermatitis—Capecitabine—prostate cancer	0.000176	0.000341	CcSEcCtD
Dextroamphetamine—Tachycardia—Doxorubicin—prostate cancer	0.000176	0.000341	CcSEcCtD
Dextroamphetamine—Headache—Capecitabine—prostate cancer	0.000175	0.000339	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Doxorubicin—prostate cancer	0.000174	0.000338	CcSEcCtD
Dextroamphetamine—Dyspnoea—Epirubicin—prostate cancer	0.000174	0.000336	CcSEcCtD
Dextroamphetamine—Somnolence—Epirubicin—prostate cancer	0.000173	0.000336	CcSEcCtD
Dextroamphetamine—Anorexia—Doxorubicin—prostate cancer	0.000172	0.000333	CcSEcCtD
Dextroamphetamine—Nausea—Docetaxel—prostate cancer	0.000171	0.000332	CcSEcCtD
Dextroamphetamine—Dyspepsia—Epirubicin—prostate cancer	0.000171	0.000332	CcSEcCtD
Dextroamphetamine—Diarrhoea—Prednisone—prostate cancer	0.00017	0.00033	CcSEcCtD
Dextroamphetamine—Decreased appetite—Epirubicin—prostate cancer	0.000169	0.000328	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000168	0.000326	CcSEcCtD
Dextroamphetamine—Fatigue—Epirubicin—prostate cancer	0.000168	0.000325	CcSEcCtD
Dextroamphetamine—Nateglinide—CYP3A4—prostate cancer	0.000167	0.0124	CrCbGaD
Dextroamphetamine—Constipation—Epirubicin—prostate cancer	0.000166	0.000323	CcSEcCtD
Dextroamphetamine—Nausea—Capecitabine—prostate cancer	0.000166	0.000322	CcSEcCtD
Dextroamphetamine—Dizziness—Prednisone—prostate cancer	0.000165	0.000319	CcSEcCtD
Dextroamphetamine—Phenelzine—CYP3A4—prostate cancer	0.000164	0.0122	CrCbGaD
Dextroamphetamine—Insomnia—Doxorubicin—prostate cancer	0.000163	0.000316	CcSEcCtD
Dextroamphetamine—Dyspnoea—Doxorubicin—prostate cancer	0.000161	0.000311	CcSEcCtD
Dextroamphetamine—Somnolence—Doxorubicin—prostate cancer	0.00016	0.00031	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Epirubicin—prostate cancer	0.000159	0.000309	CcSEcCtD
Dextroamphetamine—Dyspepsia—Doxorubicin—prostate cancer	0.000159	0.000307	CcSEcCtD
Dextroamphetamine—Vomiting—Prednisone—prostate cancer	0.000158	0.000307	CcSEcCtD
Dextroamphetamine—Rash—Prednisone—prostate cancer	0.000157	0.000304	CcSEcCtD
Dextroamphetamine—Dermatitis—Prednisone—prostate cancer	0.000157	0.000304	CcSEcCtD
Dextroamphetamine—Decreased appetite—Doxorubicin—prostate cancer	0.000157	0.000304	CcSEcCtD
Dextroamphetamine—Headache—Prednisone—prostate cancer	0.000156	0.000302	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000155	0.000301	CcSEcCtD
Dextroamphetamine—Fatigue—Doxorubicin—prostate cancer	0.000155	0.000301	CcSEcCtD
Dextroamphetamine—Urticaria—Epirubicin—prostate cancer	0.000155	0.0003	CcSEcCtD
Dextroamphetamine—Constipation—Doxorubicin—prostate cancer	0.000154	0.000299	CcSEcCtD
Dextroamphetamine—Abdominal pain—Epirubicin—prostate cancer	0.000154	0.000298	CcSEcCtD
Dextroamphetamine—Body temperature increased—Epirubicin—prostate cancer	0.000154	0.000298	CcSEcCtD
Dextroamphetamine—Nausea—Prednisone—prostate cancer	0.000148	0.000287	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000147	0.000286	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Epirubicin—prostate cancer	0.000143	0.000278	CcSEcCtD
Dextroamphetamine—Urticaria—Doxorubicin—prostate cancer	0.000143	0.000277	CcSEcCtD
Dextroamphetamine—Benzphetamine—CYP3A4—prostate cancer	0.000142	0.0106	CrCbGaD
Dextroamphetamine—Body temperature increased—Doxorubicin—prostate cancer	0.000142	0.000276	CcSEcCtD
Dextroamphetamine—Abdominal pain—Doxorubicin—prostate cancer	0.000142	0.000276	CcSEcCtD
Dextroamphetamine—Asthenia—Epirubicin—prostate cancer	0.00014	0.000271	CcSEcCtD
Dextroamphetamine—Diarrhoea—Epirubicin—prostate cancer	0.000133	0.000258	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Doxorubicin—prostate cancer	0.000133	0.000257	CcSEcCtD
Dextroamphetamine—Asthenia—Doxorubicin—prostate cancer	0.000129	0.000251	CcSEcCtD
Dextroamphetamine—Dizziness—Epirubicin—prostate cancer	0.000129	0.00025	CcSEcCtD
Dextroamphetamine—Vomiting—Epirubicin—prostate cancer	0.000124	0.00024	CcSEcCtD
Dextroamphetamine—Diarrhoea—Doxorubicin—prostate cancer	0.000123	0.000239	CcSEcCtD
Dextroamphetamine—Rash—Epirubicin—prostate cancer	0.000123	0.000238	CcSEcCtD
Dextroamphetamine—Dermatitis—Epirubicin—prostate cancer	0.000123	0.000238	CcSEcCtD
Dextroamphetamine—Headache—Epirubicin—prostate cancer	0.000122	0.000236	CcSEcCtD
Dextroamphetamine—Dizziness—Doxorubicin—prostate cancer	0.000119	0.000231	CcSEcCtD
Dextroamphetamine—Nausea—Epirubicin—prostate cancer	0.000116	0.000224	CcSEcCtD
Dextroamphetamine—Vomiting—Doxorubicin—prostate cancer	0.000115	0.000222	CcSEcCtD
Dextroamphetamine—Rash—Doxorubicin—prostate cancer	0.000114	0.00022	CcSEcCtD
Dextroamphetamine—Dermatitis—Doxorubicin—prostate cancer	0.000113	0.00022	CcSEcCtD
Dextroamphetamine—Headache—Doxorubicin—prostate cancer	0.000113	0.000219	CcSEcCtD
Dextroamphetamine—Nausea—Doxorubicin—prostate cancer	0.000107	0.000207	CcSEcCtD
Dextroamphetamine—CYP2D6—Metabolism—TCN2—prostate cancer	2.89e-05	0.000118	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTA3—prostate cancer	2.89e-05	0.000118	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKR1C3—prostate cancer	2.85e-05	0.000116	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRKACB—prostate cancer	2.83e-05	0.000115	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KRAS—prostate cancer	2.82e-05	0.000115	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—THBS1—prostate cancer	2.76e-05	0.000112	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PPP3CA—prostate cancer	2.76e-05	0.000112	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HSD3B1—prostate cancer	2.76e-05	0.000112	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC22A3—prostate cancer	2.76e-05	0.000112	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ANXA1—prostate cancer	2.72e-05	0.000111	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRKCZ—prostate cancer	2.67e-05	0.000109	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TBXAS1—prostate cancer	2.64e-05	0.000108	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTA4—prostate cancer	2.64e-05	0.000108	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CG—prostate cancer	2.61e-05	0.000106	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PIK3CA—prostate cancer	2.59e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGFR4—prostate cancer	2.58e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PARP1—prostate cancer	2.58e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTA2—prostate cancer	2.58e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTHLH—prostate cancer	2.57e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFBR1—prostate cancer	2.57e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CALCA—prostate cancer	2.55e-05	0.000104	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SULT1A1—prostate cancer	2.54e-05	0.000104	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCG5—prostate cancer	2.54e-05	0.000104	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKR1C3—prostate cancer	2.53e-05	0.000103	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKACB—prostate cancer	2.52e-05	0.000102	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—prostate cancer	2.5e-05	0.000102	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL12—prostate cancer	2.49e-05	0.000101	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTA1—prostate cancer	2.49e-05	0.000101	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NAT2—prostate cancer	2.46e-05	0.0001	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HSD3B2—prostate cancer	2.46e-05	0.0001	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTO1—prostate cancer	2.46e-05	0.0001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PPP3CA—prostate cancer	2.45e-05	9.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—THBS1—prostate cancer	2.45e-05	9.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ANXA1—prostate cancer	2.42e-05	9.84e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKCZ—prostate cancer	2.37e-05	9.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CG—prostate cancer	2.37e-05	9.65e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLCB2—prostate cancer	2.36e-05	9.58e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LRP2—prostate cancer	2.36e-05	9.58e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2C18—prostate cancer	2.36e-05	9.58e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP9—prostate cancer	2.35e-05	9.54e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CG—prostate cancer	2.32e-05	9.44e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—P4HB—prostate cancer	2.31e-05	9.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CD—prostate cancer	2.3e-05	9.34e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PARP1—prostate cancer	2.29e-05	9.33e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGFR4—prostate cancer	2.29e-05	9.33e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—prostate cancer	2.29e-05	9.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NGFR—prostate cancer	2.27e-05	9.24e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRKCQ—prostate cancer	2.27e-05	9.24e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CALCA—prostate cancer	2.26e-05	9.21e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC22A1—prostate cancer	2.25e-05	9.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAP3K7—prostate cancer	2.25e-05	9.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL12—prostate cancer	2.21e-05	9e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SULT2A1—prostate cancer	2.19e-05	8.91e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGF10—prostate cancer	2.16e-05	8.78e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MED12—prostate cancer	2.16e-05	8.77e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GNG5—prostate cancer	2.14e-05	8.7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRB2—prostate cancer	2.14e-05	8.69e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKT1—prostate cancer	2.11e-05	8.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—JAK2—prostate cancer	2.11e-05	8.57e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CG—prostate cancer	2.11e-05	8.57e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAP2K1—prostate cancer	2.1e-05	8.54e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CD—prostate cancer	2.09e-05	8.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VAV3—prostate cancer	2.08e-05	8.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP9—prostate cancer	2.08e-05	8.47e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NCOA3—prostate cancer	2.06e-05	8.38e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TGFBR2—prostate cancer	2.05e-05	8.35e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CD—prostate cancer	2.04e-05	8.3e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ITPR1—prostate cancer	2.02e-05	8.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NGFR—prostate cancer	2.02e-05	8.21e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKCQ—prostate cancer	2.02e-05	8.21e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CB—prostate cancer	2e-05	8.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAP3K7—prostate cancer	1.99e-05	8.11e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HPGDS—prostate cancer	1.96e-05	7.99e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2C19—prostate cancer	1.95e-05	7.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1R—prostate cancer	1.93e-05	7.86e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL8—prostate cancer	1.92e-05	7.82e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGF10—prostate cancer	1.92e-05	7.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—JAK2—prostate cancer	1.91e-05	7.79e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTT1—prostate cancer	1.91e-05	7.75e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ACHE—prostate cancer	1.91e-05	7.75e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRB2—prostate cancer	1.9e-05	7.72e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2A6—prostate cancer	1.88e-05	7.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—JAK2—prostate cancer	1.87e-05	7.62e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAP2K1—prostate cancer	1.86e-05	7.59e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LPL—prostate cancer	1.85e-05	7.54e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CD—prostate cancer	1.85e-05	7.54e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VAV3—prostate cancer	1.85e-05	7.53e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL2—prostate cancer	1.84e-05	7.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDGFRB—prostate cancer	1.84e-05	7.47e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKR1C3—prostate cancer	1.83e-05	7.45e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFBR2—prostate cancer	1.82e-05	7.42e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PRKACB—prostate cancer	1.82e-05	7.41e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CB—prostate cancer	1.82e-05	7.39e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP17A1—prostate cancer	1.8e-05	7.34e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ITPR1—prostate cancer	1.8e-05	7.3e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ITGB3—prostate cancer	1.79e-05	7.28e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CB—prostate cancer	1.78e-05	7.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL8—prostate cancer	1.75e-05	7.11e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB3—prostate cancer	1.74e-05	7.06e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGFR2—prostate cancer	1.73e-05	7.05e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NCOA2—prostate cancer	1.72e-05	6.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1R—prostate cancer	1.72e-05	6.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL8—prostate cancer	1.71e-05	6.95e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—JAK2—prostate cancer	1.7e-05	6.92e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL2—prostate cancer	1.67e-05	6.79e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TERT—prostate cancer	1.66e-05	6.77e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LPL—prostate cancer	1.65e-05	6.69e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.64e-05	6.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	1.63e-05	6.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	1.63e-05	6.63e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	1.61e-05	6.57e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.6e-05	6.52e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HIF1A—prostate cancer	1.59e-05	6.47e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	1.59e-05	6.46e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NQO1—prostate cancer	1.58e-05	6.44e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TH—prostate cancer	1.56e-05	6.35e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LEP—prostate cancer	1.55e-05	6.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	1.55e-05	6.31e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.54e-05	6.28e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	1.54e-05	6.27e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	1.54e-05	6.26e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CAV1—prostate cancer	1.54e-05	6.26e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KDR—prostate cancer	1.52e-05	6.19e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.52e-05	6.18e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2—prostate cancer	1.48e-05	6.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ESR1—prostate cancer	1.48e-05	6.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TERT—prostate cancer	1.48e-05	6.01e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GGT1—prostate cancer	1.47e-05	5.98e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NCOA1—prostate cancer	1.45e-05	5.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BAD—prostate cancer	1.45e-05	5.89e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.43e-05	5.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	1.41e-05	5.75e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APC—prostate cancer	1.4e-05	5.7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CG—prostate cancer	1.4e-05	5.7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EGF—prostate cancer	1.39e-05	5.63e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IRS1—prostate cancer	1.39e-05	5.63e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LEP—prostate cancer	1.38e-05	5.61e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—RXRA—prostate cancer	1.38e-05	5.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CAV1—prostate cancer	1.37e-05	5.56e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KDR—prostate cancer	1.35e-05	5.5e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GSK3B—prostate cancer	1.34e-05	5.47e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—COMT—prostate cancer	1.33e-05	5.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—INS—prostate cancer	1.33e-05	5.4e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTP1—prostate cancer	1.32e-05	5.37e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ESR1—prostate cancer	1.32e-05	5.36e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ITPR1—prostate cancer	1.3e-05	5.29e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	1.3e-05	5.29e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BAD—prostate cancer	1.29e-05	5.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1—prostate cancer	1.28e-05	5.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	1.28e-05	5.19e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	1.24e-05	5.06e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APC—prostate cancer	1.24e-05	5.06e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	1.24e-05	5.04e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	1.23e-05	5.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EGF—prostate cancer	1.23e-05	5.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IRS1—prostate cancer	1.23e-05	5.01e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TYMS—prostate cancer	1.23e-05	5e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	1.22e-05	4.96e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	1.22e-05	4.96e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTM1—prostate cancer	1.21e-05	4.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	1.21e-05	4.91e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	1.19e-05	4.86e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LPL—prostate cancer	1.19e-05	4.85e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGF2—prostate cancer	1.18e-05	4.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—INS—prostate cancer	1.18e-05	4.79e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOS3—prostate cancer	1.16e-05	4.73e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	1.15e-05	4.69e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.15e-05	4.68e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ERCC2—prostate cancer	1.14e-05	4.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1—prostate cancer	1.14e-05	4.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	1.13e-05	4.61e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JAK2—prostate cancer	1.13e-05	4.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	1.11e-05	4.51e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MDM2—prostate cancer	1.1e-05	4.49e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	1.1e-05	4.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	1.09e-05	4.45e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	1.09e-05	4.43e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.08e-05	4.41e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	1.08e-05	4.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	1.07e-05	4.37e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTHFR—prostate cancer	1.07e-05	4.36e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	1.07e-05	4.36e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPARA—prostate cancer	1.05e-05	4.28e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGF2—prostate cancer	1.05e-05	4.26e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.03e-05	4.2e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	1.03e-05	4.2e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	1.01e-05	4.1e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1e-05	4.09e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	9.97e-06	4.05e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CAV1—prostate cancer	9.9e-06	4.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	9.88e-06	4.02e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2—prostate cancer	9.86e-06	4.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	9.84e-06	4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	9.81e-06	3.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MDM2—prostate cancer	9.8e-06	3.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	9.67e-06	3.93e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	9.61e-06	3.91e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	9.54e-06	3.88e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	9.52e-06	3.87e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	9.33e-06	3.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	9.3e-06	3.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	9.28e-06	3.77e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	9.17e-06	3.73e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	9.05e-06	3.68e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CG—prostate cancer	9.01e-06	3.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	8.95e-06	3.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	8.85e-06	3.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EP300—prostate cancer	8.85e-06	3.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	8.77e-06	3.57e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2—prostate cancer	8.76e-06	3.56e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	8.72e-06	3.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SRC—prostate cancer	8.61e-06	3.5e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	8.54e-06	3.47e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—INS—prostate cancer	8.53e-06	3.47e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	8.46e-06	3.44e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	8.38e-06	3.41e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CREBBP—prostate cancer	8.36e-06	3.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	8.3e-06	3.38e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	8.29e-06	3.37e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	8.26e-06	3.36e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	8.24e-06	3.35e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	8.04e-06	3.27e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CD—prostate cancer	7.92e-06	3.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EP300—prostate cancer	7.86e-06	3.2e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—prostate cancer	7.71e-06	3.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	7.69e-06	3.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SRC—prostate cancer	7.64e-06	3.11e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	7.54e-06	3.07e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NOS3—prostate cancer	7.48e-06	3.04e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	7.44e-06	3.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	7.37e-06	3e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	7.13e-06	2.9e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CB—prostate cancer	6.91e-06	2.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—prostate cancer	6.85e-06	2.79e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—prostate cancer	6.84e-06	2.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	6.83e-06	2.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	6.7e-06	2.73e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	6.55e-06	2.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—prostate cancer	6.33e-06	2.58e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	6.33e-06	2.57e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTEN—prostate cancer	5.97e-06	2.43e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	5.81e-06	2.37e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—prostate cancer	5.8e-06	2.36e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—EP300—prostate cancer	5.69e-06	2.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—prostate cancer	5.63e-06	2.29e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	5.35e-06	2.18e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—prostate cancer	5.15e-06	2.09e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	4.75e-06	1.93e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.21e-06	1.71e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKT1—prostate cancer	3.44e-06	1.4e-05	CbGpPWpGaD
